Bulk Pharmaceutical API Sources for DILTIAZEM HYDROCHLORIDE

Bulk Pharmaceutical API Sources for DILTIAZEM HYDROCHLORIDE

Vendor	Vendor Homepage	Vendor Sku	API Url
Sigma-Aldrich		D2521_SIGMA
Calbiochem		309866
NovoSeek		62920
TCI (Tokyo Chemical Industry)		D3662
MolPort		MolPort-003-931-523

Bulk Active Pharmaceutical Ingredient (API) Sources for Diltiazem Hydrochloride

Last updated: July 29, 2025

Introduction

Diltiazem hydrochloride is a widely prescribed calcium channel blocker used to treat hypertension, angina pectoris, and certain arrhythmias. As a critical component in cardiovascular therapy, the quality, sourcing, and supply chain integrity of diltiazem hydrochloride API are paramount for pharmaceutical manufacturers. This article provides a comprehensive analysis of global API sources for diltiazem hydrochloride, highlighting manufacturing bases, regulatory compliance, supplier reliability, and evolving sourcing trends.

Manufacturing Countries and Major Producers

India and China dominate API manufacturing for diltiazem hydrochloride, accounting for a significant share of the global supply. Both countries host numerous API producers that adhere to international quality standards, such as WHO GDP, cGMP, and ISO certifications.

• India:
  Indian pharmaceutical companies, including Sun Pharma, Cadila Healthcare, and Mylan, have established extensive API production facilities capable of manufacturing high-quality diltiazem hydrochloride. Their existing infrastructure enables competitive pricing and robust supply chains. Indian API producers generally conform to USFDA, EU-GMP, or equivalent standards, ensuring access to diverse markets.

• China:
  Chinese API manufacturers, like Zhaohui Pharmaceutical and Zhejiang Orient Gene Pharmaceutical, are also key players. They offer cost-effective solutions and large production capacities. However, regulatory compliance varies, necessitating due diligence for quality assurance.

Other emerging sources include pharmaceutical hubs in Eastern Europe, Southeast Asia, and Latin America, though these are less prominent in the diltiazem API market.

Regulatory and Quality Considerations

Suppliers must meet stringent quality and regulatory demands to ensure API safety and efficacy. Regulatory agencies such as the USFDA, EMA, and WHO verify manufacturing processes through inspections and batch testing. Many Indian and Chinese API manufacturers now pursue approvals or certifications such as:

• US FDA approval or prior approval licenses for API manufacturing facilities
• EU-GMP certification
• ISO 9001 and ISO 14001 certifications

These credentials are critical for pharmaceutical companies aiming to supply markets with rigorous quality standards.

Supply Chain Reliability and Market Dynamics

Market reliability hinges on factors like:

• Production capacity
• Lead times and inventory stability
• Regulatory compliance and certifications
• Pricing dynamics

The pandemic underscored vulnerabilities in global supply chains, with some manufacturers facing disruptions. Consequently, many pharmaceutical firms diversify their API sourcing to mitigate risks.

Key API Suppliers and Distributors

Leading API suppliers for diltiazem hydrochloride include:

• Mack Pharmaceuticals (India): Known for cGMP-certified APIs, with a focus on cardiovascular drugs.
• Glenmark Pharmaceuticals (India): Contains several API manufacturing units and supplies bulk diltiazem hydrochloride.
• Zhejiang Orient Gene Pharmaceutical (China): Offers competitive pricing and large batch capacities.
• Sun Pharmaceutical Industries (India): One of the largest API producers globally, with extensive capabilities.
• Aurobindo Pharma (India): Supplies various cardiovascular APIs, including diltiazem hydrochloride.

Major API intermediaries like Aventis Pharmaceuticals and Mundipharm also facilitate distribution across North America, Europe, and Asia.

Evolving Sourcing Trends

Recent trends reflect a shift towards vertical integration and regional sourcing to ensure supply security:

• Regulatory diversification allows companies to mitigate risks associated with reliance on a single country.
• Environmental and sustainability standards influence supplier selection, especially in jurisdictions emphasizing greener manufacturing practices.
• Technological innovations in synthesis processes have improved yield and purity, influencing supplier competitiveness.

Manufacturers are increasingly seeking API sources with compliance histories aligned with current Good Manufacturing Practices (cGMP), minimizing regulatory hurdles during drug approval processes.

Quality Assurance and Due Diligence

For pharmaceutical companies, selecting API sources involves thorough assessment of:

• Certifications (USFDA, EU-GMP)
• Batch consistency and traceability
• Manufacturing process validation
• Responsiveness to regulatory audits
• Supply chain transparency

Engaging with suppliers that have robust quality management systems minimizes compliance risks and ensures uninterrupted production.

Conclusion

The API landscape for diltiazem hydrochloride is characterized by a concentration of manufacturing in India and China, with a growing emphasis on regulatory compliance, supply security, and quality assurance. Pharmaceutical companies must navigate this complex supplier environment attentively, balancing cost considerations with stringent quality standards to ensure access to high-grade API for cardiovascular therapeutics.

---

Key Takeaways

• India and China dominate the diltiazem hydrochloride API market, offering extensive capacities and cost-effective options.
• Regulatory compliance, including USFDA and EU-GMP certifications, is critical when selecting API sources.
• Supply chain resilience is increasingly important; diversified sourcing strategies mitigate risks.
• Quality assurance through rigorous due diligence ensures API batch consistency and regulatory acceptance.
• Emerging trends, such as greener manufacturing processes and technological innovations, influence API sourcing strategies.

---

Frequently Asked Questions (FAQs)

1. What are the primary countries supplying diltiazem hydrochloride API?
India and China are the leading suppliers, with additional sources emerging from other regions like Southeast Asia and Latin America.

2. Why is regulatory compliance vital when sourcing diltiazem hydrochloride API?
Regulatory compliance verifies API quality, safety, and efficacy, facilitating market access in regions with strict regulatory standards like the US and EU.

3. How do companies ensure the quality of imported APIs?
Through certifications (USFDA, EU-GMP), supplier audits, batch testing, and verifying manufacturing process validation.

4. What factors influence API price and supply stability?
Production capacity, supply chain logistics, regulatory compliance, and geopolitical factors affect prices and supply stability.

5. Are there risks associated with sourcing API from emerging markets?
Yes, including variable regulatory standards and quality control, but these can be mitigated through thorough due diligence and supplier audits.

---

Sources

[1] US Food and Drug Administration (FDA). List of Approved API Manufacturers.
[2] World Health Organization (WHO). Guidelines for Good Manufacturing Practices for Active Pharmaceutical Ingredients.
[3] Indian Pharmaceutical Alliance. API Manufacturing Capabilities and Standards.
[4] Chinese Pharmaceutical Industry Reports.

---

Note: This analysis is based on current market data and industry trends as of 2023. Suppliers' status and regulatory compliance should be independently verified.